Presentation

• Tizime Inj. 250 mg: Each vial contains Ceftazidime USP 250 mg (as a mixture of Ceftazidime pentahydrate and Sodium Carbonate) for IV/IM injection.
• Tizime Inj. 500 mg: Each vial contains Ceftazidime USP 500 mg (as a mixture of Ceftazidime pentahydrate and Sodium Carbonate) for IV/IM injection.
• Tizime Inj. 1 gm: Each vial contains Ceftazidime USP 1 gm (as a mixture of Ceftazidime pentahydrate and Sodium Carbonate) for IV/IM injection.

Description

Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. Ceftazidime is bactericidal in action exerting its effect by inhibition of enzymes responsible for cell-wall synthesis. A wide range of gram-negative organisms is susceptible to ceftazidime in vitro, including strains resistant to gentamicin and other aminoglycosides. In addition, ceftazidime has been shown to be active against gram-positive organisms. It is highly stable to most clinically important beta-lactamases, plasmid or chromosomal, which are produced by both gram-negative and gram-positive organisms and, consequently, is active against many strains resistant to ampicillin and other cephalosporins.

Therapeutic Class: Antibiotics